share_log

The Total Return for Shandong Pharmaceutical GlassLtd (SHSE:600529) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years

The Total Return for Shandong Pharmaceutical GlassLtd (SHSE:600529) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years

在過去五年中,山東藥用玻璃有限公司(SHSE: 600529)投資者的總回報增長速度超過了收益的增長
Simply Wall St ·  05/30 18:28

When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying the right stocks can give your wealth a significant boost. For example, the Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529) share price is up 40% in the last 5 years, clearly besting the market return of around 14% (ignoring dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 3.8% in the last year, including dividends.

我們在投資時一般尋求跑贏市場平均水平的股票。經過我們的經驗來看,買入正確的股票可以顯著提高財富。例如,山東藥玻(SHSE:600529)股價在過去5年中上漲了40%,明顯跑贏了市場回報約14%的狀況(忽略分紅)。然而,近期回報並不像那樣令人印象深刻,包括分紅在內,股票在過去一年中僅返回3.8%。

While the stock has fallen 3.2% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

儘管本週股票下跌了3.2%,但值得關注的是更長期的歷史回報,並查看這些回報是否由基本面推動。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

雖然有效市場假說仍然被一些人教授,但被證明市場是過度反應的動態系統,投資者並不總是理性的。檢查市場情緒如何隨時間變化的一種方法是看一個公司的股價與其每股收益(EPS)之間的交互作用。

During five years of share price growth, Shandong Pharmaceutical GlassLtd achieved compound earnings per share (EPS) growth of 14% per year. This EPS growth is higher than the 7% average annual increase in the share price. So it seems the market isn't so enthusiastic about the stock these days.

在股票價格增長的五年中,山東藥玻股份股份有限公司實現了每股收益增長的複合年增長率爲14%。這種每股收益增長高於7%的股票價格年均增長率。因此,看起來市場對該股票並不那麼熱衷。

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

該公司的每股收益(隨時間的推移)如下圖所示(單擊可查看確切數字)。

earnings-per-share-growth
SHSE:600529 Earnings Per Share Growth May 30th 2024
SHSE:600529每股收益增長2024年5月30日

We know that Shandong Pharmaceutical GlassLtd has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts.

我們知道山東藥玻股份股份有限公司最近改善了其底線,但它是否會增加營業收入呢?您可以查看這份顯示分析師預測的營業收入的免費報告。

What About Dividends?

那麼分紅怎麼樣呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for Shandong Pharmaceutical GlassLtd the TSR over the last 5 years was 46%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return.

對於任何給定的股票,考慮總股東回報和股票價格回報都很重要。TSR包括任何分拆或折價籌資的價值,以及基於股息被再投資的假設而支付的任何股息。股息派發給股東,從而提高股東回報。我們注意到,對於山東藥玻有限公司而言,過去5年的TSR爲46%,優於上述股票價格回報。該公司支付的股息已促使其TSR得以提高。股東回報。

A Different Perspective

不同的觀點

It's nice to see that Shandong Pharmaceutical GlassLtd shareholders have received a total shareholder return of 3.8% over the last year. And that does include the dividend. However, that falls short of the 8% TSR per annum it has made for shareholders, each year, over five years. Potential buyers might understandably feel they've missed the opportunity, but it's always possible business is still firing on all cylinders. Is Shandong Pharmaceutical GlassLtd cheap compared to other companies? These 3 valuation measures might help you decide.

山東藥玻股份股份有限公司股東在過去一年中獲得了3.8%的總股東回報。這確實包括分紅。然而,與它在過去5年爲股東每年創造的8%的TSR相比,這還不到。潛在的買家可能會理解地認爲他們錯過了機會,但業務仍然可能在全速運行。山東藥玻股份股份有限公司是否與其他公司相比便宜?這3個估值措施可能有助於您作出決定。

If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.

如果您像我一樣,就不會希望錯過這份免費的內部人士正在購買的低估小市值股票列表。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論